Eleven years of Inflexal® V-a virosomal adjuvanted influenza vaccine

被引：193

作者：

Herzog, Christian ^{[1
]}

Hartmann, Katharina ^{[1
]}

Kuenzi, Valerie ^{[1
]}

Kuersteiner, Oliver ^{[1
]}

Mischler, Robert ^{[1
]}

Lazar, Hedvika ^{[1
]}

Glueck, Reinhard ^{[1
]}

机构：

[1] Berna Biotech AG, CH-3018 Bern, Switzerland

来源：

VACCINE | 2009年 / 27卷 / 33期

关键词：

Influenza vaccine; Virosomes; Adjuvant; Inflexal (R) V; HIV-INFECTED CHILDREN; AGED; 3-14; YEARS; COST-EFFECTIVENESS; IMMUNOGENICITY; SUBUNIT; DELIVERY; SAFETY; TRIVALENT; TOLERABILITY; EFFICACY;

D O I：

10.1016/j.vaccine.2009.05.029

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech Ltd.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal (R) V. Since 1992, 29 company sponsored clinical studies investigating the efficacy and safety of Inflexal (R) V have been completed in which 3920 subjects participated. During its decade on the market, Inflexale (R) V has shown an excellent tolerability profile due to its biocompatibility and purity. The vaccine contains no thiomersal or formaldehyde and its purity is reflected in the low ovalbumin content. By mimicking natural infection, the vaccine is highly efficacious. Inflexal (R) V is the only adjuvanted influenza vaccine licensed for all age groups and shows a good immunogenicity in both healthy and immunocompromised elderly, adults and children. This review presents and discusses the experience with Inflexal (R) V during the past decade. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：4381 / 4387

页数：7

共 76 条

[1] Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users [J].